A 10-member U.S. expert panel offers the first structured operational framework for EAA-guided polymyxin B hemoadsorption, including a direct antimicrobial dosing statement relevant to stewardship pharmacists, even though recent Surviving Sepsis Campaign guidelines suggest against the therapy.
📅 Journal publication: Jul 29, 2026·Last updated: Nov 2, 2026
PMX-HA consensuspolymyxin B hemoadsorptionDelphi panel (Vantive-sponsored)endotoxic septic shockEndotoxin Activity Assayextracorporeal blood purificationantimicrobial adsorptionCritical Care 2026Critical Care / ICU
Polymyxin B guidelines target septic shock precision therapy.
Polymyxin B hemoadsorption (PMX-HA) offers a targeted intervention for endotoxic septic shock, with potential to improve outcomes when implemented correctly. 20 consensus statements include criteria for endotoxemia assessment, use of the Endotoxin Activity Assay (EAA), and standardized protocols for PMX-HA. The structured framework helps clinicians identify eligible patients, with specific EAA thresholds supporting treatment decisions. However, regulatory approval is still pending in the U.S. Consensus guidelines provide a framework for PMX-HA in septic shock, pending U.S. approval.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Citation:Yessayan L, Legrand M, Neyra JA, et al. Consensus recommendations for patient selection and clinical implementation of polymyxin B hemoadsorption in endotoxic septic shock. Critical care (London, England). 2026;30(1). doi:10.1186/s13054-026-06182-8